Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions reflect a balanced view, with posts mentioning the neutral effects of insulin glargine on heart outcomes from the ORIGIN trial, specific data on weight gain, and references to interpretations of the findings, all conveying a nuanced understanding and recognition of the potential clinical implications.
Most discussions acknowledge the findings of the ORIGIN trial, with some expressing cautious optimism about insulin's safety and effects on cardiovascular outcomes.
The posts show moderate interest, with individuals referencing specific studies and data, indicating engagement with the research findings.
Participants discuss detailed aspects of insulin therapy, weight gain, and cardiovascular impacts, demonstrating thoughtful engagement and analysis.
The discussions suggest that the consensus recognizes the study's importance in understanding insulin's safety profile, indicating a moderate to high perceived impact.
Elegant studies in mice link aspartame to accelerated #atherosclerosis through enhanced #insulin action. https://t.co/IErs21vcTT Yet in humans #T2D insulin Rx in the ORIGIN trial was not linked to increased rates of #heartdisease https://t.co/2OcvpUVINT https://t.co/A5NZoNI2Ae
There are many ways to interpret the ORIGIN trial, yet raising insulin levels by exogenous #insulin therapy for 6 yrs in PPL with IFG, IGT or #T2D many with pre-existing hyperinsulinemia, had no discernible effects on the heart and major CV outcomes https://t.co/ya7ofsUMLa https://t.co/TyCzLNlOPI
@StephenORahilly Given the likely (very small) effect size and multiple confounders of *potential* changes in body weight with sustained higher or lower #insulin levels, the feasibility and interpretation of any “definitive’ prospective study is highly uncertain https://t.co/ya7ofsUMLa
@whsource @JimJohnsonSci @RonZimmernPHG @jfchen1 @StephenORahilly @GilesYeo @MRC_Epid @davidludwigmd 6 years of daily insulin glargine 0.4Units/kg A 1.6 kg mean weight gain ~300 grams a year, despite more #hypoglycemia with insulin in the ORIGIN study. Many study participants don’t gain any weight https://t.co/ya7ofsUMLa
@JimJohnsonSci @annizubc Interesting! Looking forward to read! Why no pancreatic cancer signal in insulin trials like ORIGIN? “…insulin glargine [for more than 6 years] had a neutral effect on cardiovascular outcomes and cancers” (n=12,500) https://t.co/Ha6YUNFdlo
@ArsenaultBenoit @egagnon_phd Nice paper! It could be interesting to consider the MR results in context of weight gain after administration of exogenous insulin (such as ORIGIN trial https://t.co/ThDo4mcVJU)
Prof Jörg Bojunga explains the optimal medication strategies for Type 2 Diabetes based on the National Guideline, discussing various drug classes and recent studies on insulin and cardiovascular outcomes.
There are 2 big lies about Type 2 Diabetes. It is often seen as a progressive, incurable disease, but in reality, it is primarily a lifestyle and nutritional disorder that can be reversed through dietary changes…
Prof Johannes Mann presents the FLOW study results demonstrating the nephroprotective effects of Semaglutide in 3533 chronic kidney disease patients, emphasizing recent advances in managing blood pressure in CKD.
RT @DanielJDrucker: Elegant studies in mice link aspartame to accelerated #atherosclerosis through enhanced #insulin action. https://t.co/I…
RT @DanielJDrucker: Elegant studies in mice link aspartame to accelerated #atherosclerosis through enhanced #insulin action. https://t.co/I…
RT @DanielJDrucker: Elegant studies in mice link aspartame to accelerated #atherosclerosis through enhanced #insulin action. https://t.co/I…
RT @DanielJDrucker: Elegant studies in mice link aspartame to accelerated #atherosclerosis through enhanced #insulin action. https://t.co/I…
RT @DanielJDrucker: Elegant studies in mice link aspartame to accelerated #atherosclerosis through enhanced #insulin action. https://t.co/I…
RT @DanielJDrucker: Elegant studies in mice link aspartame to accelerated #atherosclerosis through enhanced #insulin action. https://t.co/I…
RT @DanielJDrucker: Elegant studies in mice link aspartame to accelerated #atherosclerosis through enhanced #insulin action. https://t.co/I…
RT @DanielJDrucker: Elegant studies in mice link aspartame to accelerated #atherosclerosis through enhanced #insulin action. https://t.co/I…
Elegant studies in mice link aspartame to accelerated #atherosclerosis through enhanced #insulin action. https://t.co/IErs21vcTT Yet in humans #T2D insulin Rx in the ORIGIN trial was not linked to increased rates of #heartdisease https://t.co/2OcvpUVINT https://t.co/A5NZoNI2Ae
RT @BoussageonR: @hiraethdufutur @MG_Dr_Troll @Ordoscopie @MahlerNord Ce qui n'est pas rassurant, c'est que l'insuline soit équivalente à d…
@hiraethdufutur @MG_Dr_Troll @Ordoscopie @MahlerNord Ce qui n'est pas rassurant, c'est que l'insuline soit équivalente à des médicaments inefficaces et dangereux ... https://t.co/qklgEhaqhI
@ArsenaultBenoit @egagnon_phd Nice paper! It could be interesting to consider the MR results in context of weight gain after administration of exogenous insulin (such as ORIGIN trial https://t.co/ThDo4mcVJU)
There are many ways to interpret the ORIGIN trial, yet raising insulin levels by exogenous #insulin therapy for 6 yrs in PPL with IFG, IGT or #T2D many with pre-existing hyperinsulinemia, had no discernible effects on the heart and major CV outcomes https://t.co/ya7ofsUMLa https://t.co/TyCzLNlOPI
RT @Filip_Knop: @JimJohnsonSci @annizubc Interesting! Looking forward to read! Why no pancreatic cancer signal in insulin trials like ORIGI…
RT @Filip_Knop: @JimJohnsonSci @annizubc Interesting! Looking forward to read! Why no pancreatic cancer signal in insulin trials like ORIGI…
@JimJohnsonSci @annizubc Interesting! Looking forward to read! Why no pancreatic cancer signal in insulin trials like ORIGIN? “…insulin glargine [for more than 6 years] had a neutral effect on cardiovascular outcomes and cancers” (n=12,500) https://t.co/Ha6YUNFdlo
24c)
@JimJohnsonSci @AbdTahrani @Dr__Guess @DrNadolsky @dr_muniyappa @davidludwigmd FWIW, in people with dysglycemia at trial entry in ORIGIN (n=12,537) treated with #insulin glargine (28 units for 70 kg person) for a mean F/U of 6 years, differential weight gain was 1.6 kg, about the same as one could gain over a festive holiday weekend https://t.co/vOH3k75reV
@KevinH_PhD "Median weight increased by 1.6 kg in the insulin-glargine group and fell by 0.5 kg in the standard-care group. " https://t.co/ucQpibEQaw https://t.co/ji5bM1rhju
RT @DanielJDrucker: @StephenORahilly Given the likely (very small) effect size and multiple confounders of *potential* changes in body weig…
@StephenORahilly Given the likely (very small) effect size and multiple confounders of *potential* changes in body weight with sustained higher or lower #insulin levels, the feasibility and interpretation of any “definitive’ prospective study is highly uncertain https://t.co/ya7ofsUMLa
Como se trata de una #IGlar, su seguridad CV se ha considerado a raíz del estudio #ORIGIN (Outcome Reduction with Initial Glargine Intervention) en el que se confirmó su seguridad CV y en aparición de cáncer. https://t.co/3GUh8BIc3r https://t.co/XeTqr27Rx5
@whsource @JimJohnsonSci @RonZimmernPHG @jfchen1 @StephenORahilly @GilesYeo @MRC_Epid @davidludwigmd 6 years of daily insulin glargine 0.4Units/kg A 1.6 kg mean weight gain ~300 grams a year, despite more #hypoglycemia with insulin in the ORIGIN study. Many study participants don’t gain any weight https://t.co/ya7ofsUMLa
@armyofdan @Maratosflier @OramedPharma @diabetes @reboundhigh Most agree that peripheral hyperinsulinemia likely not a good thing, adverse for CV risk. Just exceptionally difficult to prove beyond small studies and biomarkers @NEJM https://t.co/emzF2ReWtr